Podcasts about Akorn

Un fracaso más para las Chivas, además de no tener los resultados esperados en lo deportivo, en las próximas horas se debe confirmar la salida de su entrenador, Fernando Gago, para dirigir a Boca Juniors.Te contamos cómo va el proceso, qué hace falta para que se vaya y quiénes son los posibles reemplazantes del argentino, que no tuvo un buen paso por  el conjunto de Guadalajara.Además te traemos toda la información sobre las eliminatorias sudamericanas, la Nations League en Europa y todos los resultados de las Grandes Ligas que ya están por definir los juegos de la Serie Mundial. Mantente actualizado con lo último de 'TUDN Podcast'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'TUDN Podcast' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

Today, Shivam talks about how a private plane manufacturer is in a cross-national pickle and pressing issues in the pharmaceutical industry. Topics discussed: How an Airplane manufacturer is seeing legal complications How big pharma company and Akorn pharma is seeing price challenges Links mentioned in this episode: https://invstr.com/cirrus-aircraft-owned-by-sanctioned-chinese-manufacturer/ https://invstr.com/prescription-and-inflation-us-drug-shortage/ https://invstr.com/market-recap-july-17th-2023/

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 15, live from Eyecelerator :37 ·       Preview of episode 17, live at Octane OTF 1:07s ·       Théa to acquire seven branded ophthalmic products from Akorn 2:17 ·       FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11 ·       OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56 ·       ‘One of my greatest honors': Jim Mazzo awarded Ellis Island Medal of Honor 10:38 ·       Introduction Stephen McLeod, MD 12:14 ·       What's been your biggest challenge transitioning from clinical practice to your current position? 14:16 ·       Where is the AAO going now? 17:50 ·       Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59 ·       The future of meetings 30:27 ·       Preview of episode 17 35:44 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:47 ·       Thanks for listening 54:02 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. McLeod is the CEO of the American Academy of Ophthalmology.

Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.

With over 100 film and television credits to his name, award-winning actor, Adrian Holmes, has become one to watch in the entertainment industry. He can be seen starring opposite Ian Somerhalder, in the Netflix vampire-drama series, "V Wars" based on the popular bestselling book series by Jonathan Maberry. The series follows Dr. Luther Swann (Somerhalder) who enters a world of untold horror when a mysterious virus transforms his best friend, Michael Fayne (Holmes), into a murderous predator.On the film front, Holmes can be seen in the Universal Pictures' action-thriller "Skyscraper" alongside Dwayne 'The Rock' Johnson.Holmes is well-known for starring as Nick Barron on Bravo's original award winning series, "19-2" and for his portrayal of Captain Pike on the long running CW series, "Arrow." In 2017, he took home Canada's top honor in film and television for "19-2," with the Canadian Screen Award for Best Male Lead in a Dramatic Series. The show also won Best Drama series at the 2016 Canadian Screen Awards and was also nominated for a 2016 International Emmy Award. "19-2" is now streaming on Crave TV, Akorn, and Amazon.In addition to working in front of the camera, Holmes received a producer credit, for co-producing, alongside Step by Step Productions, the docudrama "Barrow: Freedom Fighter", which was shot in his homeland of Barbados.Additional film credits include Sony/TriStar Pictures' "Elysium" & "Debug", WWE Studios' "Vendetta," "Frankie & Alice", IFC's "Wrecked", and Warner Bros' "Red Riding Hood".Born in Wrexham, North Wales, with family from Barbados, Holmes grew up in and around Vancouver, British Columbia. The eldest of three boys, Holmes was a natural entertainer as a child. In junior high school, his drama class wrote a play for a local drama festival called, "The Challenge: An Environmental Happening" which was awarded Outstanding Junior Play, and Holmes awarded Outstanding Junior Actor. From that moment on he knew he wanted to pursue a career in acting.He continued to perform in stage productions throughout high school and college and studied his craft in Vancouver with a few different coaches including world-renowned coach Larry Moss, and Ivana Chubbuck. He also studied in New York at Black Nexxus Inc. held at the Times Square Arts Centre.In 2004, Holmes received his first LEO Award nomination [the Canadian Emmys], for his work in the series "The Collector" and then again in 2017 for his work in "19-2." In 2020 he had won for his work in the comedy Web-Series, "Hospital Show".When he isn't working, Holmes enjoys traveling, and tries to get back to see his family in England and Barbados as much as possible. He likes to keep active in his down time and is always up for a good round of golf. Holmes splits his time between Vancouver, LA and London. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Geoffrey joins Terrance and Charlie to do a lot of catching up since February. (3:20) We talk about Geoff's trip to Memphis in May (24:20)What National BBQ month means to Geoff (33:30) Geoff gives us his impressions on the new Char-Griller Akron Auto-Kamado (44:50) Terrance talks to Geoff about hot wing cooks (46:45) Geoff talks about Black Smoke Barbecue and what it means for the culture (51:54) Terrance talks about wanting to do more videos and we cut up and have some good laughs Check out Geoff's latest video: https://youtu.be/qxRiLrZbQxw Geoff's Linktree: https://linktr.ee/OutdoorsWithGeoff Find Terrance's work over at: https://thebrownsugarcafe.blog/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/blacksmokebarbecue/message Support this podcast: https://podcasters.spotify.com/pod/show/blacksmokebarbecue/support

COLUMBA LIVE On LIVE FM - Akorn Design Brief by Ralph Barba

CNCO y BTS se disputan la cima; vuelve un clásico de Mariah Carey; Harry Styles, Camilo, Tini & Alejandro Sanz y mucho más

Come hang out with me as I take you on a small journey to the end of the road for my Char-Griller Akorn (Kamado grill). Along this journey I talk you through me trying out a new technique (new to me) for grilling steak. Subscribe to the show via Apple Podcasts, Google Podcasts or your favorite podcast application --- Send in a voice message: https://anchor.fm/themavcast/message Support this podcast: https://anchor.fm/themavcast/support

The Americas Core Credit team at Reorg previews what's to come in the week ahead and reviews bankruptcies from this past week including Akorn, Centric Brands and Exide Technologies. If you are not a Reorg client, request access here: go.reorg-research.com/Podcast-Trial.

On this episode of Stereo Decisis, Oliver Pulleyblank, Hilary Young and Robert Danay are joined by Angela Swan, who was recently described as "nothing short of a venerated celebrity in both Canadian contract law and the Canadian legal community at large." Angela brings her decades of experience and expertise to discuss COVID-19 and contractual clauses such as force majeure and material adverse event/change. In so doing, she mentions Akorn, Inc. v. Fresenius Kabi AG - No. 2018-0300-JTL, 2018 Del. Ch. LEXIS 325 (Ch. Oct. 1, 2018), which is one of the only cases in which a court actually found that a material adverse change clause was properly invoked by a party to a contract. In obiter dicta, Hilary recommends a podcast called My Dad Wrote a Porno, Oliver recommends the Raven DeBriefs podcast and Rob recommends a Netflix documentary called Circus of Books. If you enjoyed this podcast, please give us a rating and a review on Apple Podcasts, Stitcher, Spotify, Google Podcasts or wherever you listen to podcasts. Find us on Twitter and Facebook!

For this episode of the OIS Podcast, we are sharing a panel discussion on Leadership which took place during the last OIS@AAO meeting in San Francisco.The focus of the conversation was on “How to Measure and Motivate in a Startup Environment” and featured some valuable insights from Adrienne Graves, Bernie Haffey, Ron Kurtz, Kirk Nielsen, and Andy Corley.Participants:Adrienne Graves, PhD, Independent Board Member - Nicox, IVERIC, Oxurion, Akorn, Greenbrook TMS, Surface PharmaBernie Haffey, President - Haffey & Co.Ron Kurtz, MD, President & CEO - RxSightKirk Nielsen, Managing Partner - Vensana CapitalModerated By:Andy Corley, Principal - Yelroc ConsultingJoin us this year at the 12th Annual OIS – November 12, 2020 » Las Vegas, NVhttps://ois.net/12th-annual-ois

Jimmy and Roya talk about all things cataracts including its history, treatment and more.SOURCEShttps://www.preventblindness.org/prevent-blindness-eye-health-and-safety-observance-calendarGoogle Predicts Conjunctivitis: https://www.reviewofoptometry.com/article/catching-red-eye-epidemicswith-the-webLotemax Goes Generic via Akorn: https://www.healio.com/ophthalmology/cornea-external-disease/news/online/%7B1090824e-4033-4e6e-8809-f6ac8916f7a9%7D/fda-approves-generic-loteprednol-etabonate-from-akornEvolution of Cataract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139750/

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Roche, Novartis, Amgen, Merk, Fresenius, Akorn, Bioscience Genomics, Biogen, AIFA, Intercept.Persone: Paul Hudson (Novartis), Belén Garijo (Merk), Alessandro Fiocchi (Ospedale Pediatrico Bambino Gesù), Rino Rappuoli, Giuseppe Remuzzi, Carlamaria Zoja, Ariela Benigni, Andrea Mancuso (Ospedale San Camillo Forlanini), Richard Finkel (Nemours Children’s Hospital di Orlando), Mario Melazzini (AIFA), Robert Mitchell-Thain (Pbc Foundation).Nuove terapie: erenumab, vaccinazione per via cutanea, trapianto iPS, helixafè, nusinersen, epclusa.Patologie: emicrania, allergie alimentari, degenerazione maculare senile, atrofia muscolare spinale, epatite C, colangite biliare primitiva.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Roche, Novartis, Amgen, Merk, Fresenius, Akorn, Bioscience Genomics, Biogen, AIFA, Intercept.Persone: Paul Hudson (Novartis), Belén Garijo (Merk), Alessandro Fiocchi (Ospedale Pediatrico Bambino Gesù), Rino Rappuoli, Giuseppe Remuzzi, Carlamaria Zoja, Ariela Benigni, Andrea Mancuso (Ospedale San Camillo Forlanini), Richard Finkel (Nemours Children’s Hospital di Orlando), Mario Melazzini (AIFA), Robert Mitchell-Thain (Pbc Foundation).Nuove terapie: erenumab, vaccinazione per via cutanea, trapianto iPS, helixafè, nusinersen, epclusa.Patologie: emicrania, allergie alimentari, degenerazione maculare senile, atrofia muscolare spinale, epatite C, colangite biliare primitiva.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

Missteps on repeal-and-replace mean business as usual for insurers, and first quarter results suggest that's a good thing. Also, Fresenius acquires Akorn, and Express Scripts' ongoing battle with Anthem "gets real".

Today in FirstWord:

Rangeley Capital’s Portfolio Managers, Andrew Walker and Chris DeMuth, discuss Fondul's large discount to NAV, what's happening with Akorn, and closed end funds in general

Today in FirstWord: